- Home
- GLPI vs INSM Comparison
GLPI vs INSM Comparison
Compare GLPI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPI
- INSM
- Stock Information
- Founded
- GLPI 2013
- INSM 1988
- Country
- GLPI United States
- INSM United States
- Employees
- GLPI N/A
- INSM N/A
- Industry
- GLPI Real Estate Investment Trusts
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- GLPI Real Estate
- INSM Health Care
- Exchange
- GLPI Nasdaq
- INSM Nasdaq
- Market Cap
- GLPI 13.1B
- INSM 14.3B
- IPO Year
- GLPI N/A
- INSM 2000
- Fundamental
- Price
- GLPI $49.12
- INSM $81.06
- Analyst Decision
- GLPI Buy
- INSM Strong Buy
- Analyst Count
- GLPI 16
- INSM 15
- Target Price
- GLPI $53.38
- INSM $92.00
- AVG Volume (30 Days)
- GLPI 981.5K
- INSM 1.8M
- Earning Date
- GLPI 02-20-2025
- INSM 02-20-2025
- Dividend Yield
- GLPI 6.19%
- INSM N/A
- EPS Growth
- GLPI 3.61
- INSM N/A
- EPS
- GLPI 2.87
- INSM N/A
- Revenue
- GLPI $1,531,546,000.00
- INSM $363,707,000.00
- Revenue This Year
- GLPI N/A
- INSM $20.03
- Revenue Next Year
- GLPI $5.51
- INSM $41.61
- P/E Ratio
- GLPI $17.11
- INSM N/A
- Revenue Growth
- GLPI 6.33
- INSM 19.17
- 52 Week Low
- GLPI $41.80
- INSM $21.92
- 52 Week High
- GLPI $52.60
- INSM $84.87
- Technical
- Relative Strength Index (RSI)
- GLPI 53.74
- INSM 58.18
- Support Level
- GLPI $48.44
- INSM $79.50
- Resistance Level
- GLPI $49.95
- INSM $80.28
- Average True Range (ATR)
- GLPI 0.83
- INSM 2.98
- MACD
- GLPI 0.04
- INSM 0.06
- Stochastic Oscillator
- GLPI 56.65
- INSM 63.38
About GLPI Gaming and Leisure Properties Inc.
Gaming and Leisure Properties Inc, or GLP, is a real estate investment property trust whose primary business consists of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The GLPI's portfolio consisted of interests in sixty one gaming and related facilities, the real property associated with thirty four gaming and related facilities operated by PENN, the real property associated with six gaming and related facilities operated by Caesars Entertainment Corporation.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.